AB Science updates on masitinib clinical development

Biotechnology company AB Science has provided an update on the clinical development of masitinib, the company's lead drug candidate. Masitinib, a small molecule tyrosine kinase inhibitor, is currently being evaluated in multiple clinical studies across various therapeutic areas.

The development efforts are focused on masitinib's potential in oncology, including for the treatment of certain cancers. The company is also investigating its application in neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and multiple sclerosis.

Furthermore, AB Science is progressing with studies of masitinib for inflammatory conditions. These include chronic inflammatory demyelinating polyneuropathy (CIDP) and the treatment of gastrointestinal mastocytosis. The company has previously received feedback from regulatory authorities regarding these indications.

This update underscores AB Science's ongoing commitment to exploring masitinib's therapeutic potential for complex diseases. The company continues to advance its clinical trials and development programs.